
X
Circassia gets dual boost for US COPD drugs
https://pharmaphorum.com/news/circassia-gets-dual-boost-for-us-copd-drugs/
The UK biotech company is putting its huge failure in allergy treatment behind it. But British venture capital leader David Grainger is highly critical of the company’s execs, and says lessons need to be learnt.
UK biotech to focus on respiratory drugs after house dust mite therapy fails.
FDA rejects blood potassium drug for second time.
Chief executive Steve Harris confident company can bounce back